Promise and Pitfalls of Human Papilloma Virus Vaccine: An Updated Review

The human papilloma virus (HPV) is a primary cause of cervical cancer which is a global health concern. Even though there is a lot of evidence that HPV vaccinations prevent diseases linked to HPV, there are also many unanswered questions about the vaccines. Moreover, the high incidence of HPV-related malignancies highlights serious gaps in the vaccination coverage and education. The unequal distribution of vaccination programs is one of the main reasons why the prevalence of HPV-related malignancies remains high. Many low- and middle-income nations find it difficult to establish and maintain HPV vaccination programs, despite the fact that certain high-income countries have successfully reduced the prevalence of HPV infections via intense vaccination efforts. Due to lack of infrastructure, logistics, and resources, as well as restricted access to healthcare, vaccination rates in poor developing countries continue to fall considerably short of what is required to establish herd immunity. The issue is made worse by inadequate healthcare systems, such as the absence of school-based immunization programs and challenges in reaching rural communities. However, both men and women are at risk of acquiring avoidable malignancies in nations with low vaccination rates, contributing to the global health imbalance. To increase the efficacy of the HPV vaccination, suggestions are made for raising public awareness, expanding accessibility, and doing long-term research.